Welcome to our dedicated page for Dentsply Sirona news (Ticker: XRAY), a resource for investors and traders seeking the latest updates and insights on Dentsply Sirona stock.
DENTSPLY SIRONA Inc. develops, manufactures and markets professional dental products, dental technologies, oral health products and other consumable medical devices under a broad brand portfolio. News for XRAY commonly covers quarterly results, outlook updates, restructuring actions, capital allocation, debt reduction, share repurchases and changes to distribution relationships for dental equipment and connected technology solutions.
Company updates also focus on digital dentistry and imaging products, including CEREC systems, intraoral scanning, CBCT imaging, DS Core, Smart View - Detect and dental-dedicated MRI work with Siemens Healthineers. Additional product news includes Surity urinary incontinence devices from Wellspect HealthCare, along with regulatory clearances, CE markings, commercial launches, board changes and investor conference participation.
DENTSPLY SIRONA reported a challenging FY22 with net sales decreasing by 7.3% to $3,922 million, compared to $4,231 million in FY21. The company experienced a net loss of $950 million or ($4.41) per share, significantly down from a net income of $411 million in FY21. Q4 showed a 10.9% drop in net sales to $983 million, with adjusted EPS falling 44.4% to $0.46. For FY23, the outlook suggests net sales between $3.85 billion and $3.95 billion, with adjusted EPS anticipated in the range of $1.80 to $2.00.
Dentsply Sirona (Nasdaq: XRAY) announced a major organizational restructuring plan aimed at boosting operational efficiency and shareholder value. The plan is expected to yield between $200 million and $225 million in annual cost savings over the next 18 months. Key components include an 8%-10% workforce reduction, establishment of five global business units, and an optimized management structure. Additionally, the company anticipates $165 million in non-recurring charges, mainly in 2023, while aiming for adjusted earnings of $3.00 per share by 2026. The restructuring aligns with Dentsply Sirona's strategy to address a challenging external environment while fostering sustainable growth.
Dentsply Sirona, a leading manufacturer of dental products, will host an investor conference call and live webcast on February 28, 2023, at 8:30 am ET. This event aims to discuss the company’s fourth quarter and full year 2022 financial results. Interested participants can find the presentation and register for the call on Dentsply Sirona's Investor Relations website at https://investor.dentsplysirona.com. A replay of the webcast will also be accessible afterward. Dentsply Sirona is headquartered in Charlotte, North Carolina, and is known for its innovative dental technologies.
Dentsply Sirona (Nasdaq: XRAY) presented at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023. The company forecasts net sales exceeding $3.88 billion, surpassing its previous outlook range of $3.85 billion to $3.88 billion. The adjusted EPS for the full year 2022 is anticipated to remain within the prior guidance of $1.90 to $2.00. Presentation materials and webcast details are accessible on the company's investor website.
DENTSPLY SIRONA (Nasdaq: XRAY) will participate in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 am PT (1:30 pm ET). A live audio webcast of the presentation will be accessible via the company's investors section on their website. Dentsply Sirona, headquartered in Charlotte, North Carolina, is the world's largest manufacturer of professional dental products, providing innovative solutions that enhance patient care and safety.
Dentsply Sirona (Nasdaq: XRAY) has declared a quarterly cash dividend of $0.125 per share, translating to an indicated annual rate of $0.50 per share. The dividend will be payable on January 13, 2023, to shareholders on record as of December 30, 2022. This move reflects the company’s commitment to returning value to its shareholders while continuing its longstanding history in the dental industry.
Dentsply Sirona reported third-quarter 2022 net sales of $947 million, down by 8.9% year-over-year, with a GAAP loss of $5.01 per share. Adjusted EPS fell by 31.5% to $0.41. Key factors included foreign currency impacts and macroeconomic headwinds, with organic sales slightly declining by 0.7%. The company initiated a comprehensive review to enhance execution and return to growth. Full-year guidance reflects an expected organic sales decline of approximately 2% and adjusted EPS projected between $1.90 and $2.00.
Dentsply Sirona (Nasdaq: XRAY) announced its participation in two key upcoming healthcare conferences. The first is the Jefferies 13th Annual London Healthcare Conference scheduled for November 17, 2022, at 12:20 pm GMT (7:20 am ET). The second is the Evercore ISI 5th Annual HealthCONx Conference on December 1, 2022, at 1:00 pm ET. Interested investors can access live webcasts of these presentations via the Dentsply Sirona website. As the world's largest manufacturer of dental products, Dentsply Sirona focuses on innovative solutions for patient care.
Dentsply Sirona (Nasdaq: XRAY) will host an investor conference call and live webcast on November 14, 2022, at 8:30 am ET to discuss its third quarter financial results. Investors can access a presentation on the Company's website at this link. To participate in the call, registration is required via this page. A replay of the conference call will also be available online.
As the largest manufacturer of dental products, Dentsply Sirona focuses on advancing patient care through innovative solutions.
DENTSPLY SIRONA (Nasdaq: XRAY) announced the conclusion of its internal investigation into financial reporting issues, resulting in restatements for Q3 2021 and full-year 2021. The Audit and Finance Committee identified material weaknesses in internal controls. The company expects a goodwill impairment charge between $1.0 billion and $1.3 billion due to economic factors. Preliminary Q3 2022 net sales are projected at $947 million, reflecting organic sales decline. DENTSPLY anticipates low-single-digit sequential net sales decline for Q4 2022 but expects flat growth on a constant currency basis.